TheraVet announced the signing of an exclusive distribution agreement with Vetpharma. This agreement represents a significant step forward for the distribution of BIOCERA-VET® product range, which is now available in the five continents. Altogether this agreement covers 24 countries representing over 150 million of dogs and where the awareness of animal healthcare needs is currently increasing, particularly in major countries like the Scandinavians, Australia, Japan, South Africa and Brazil where a CAGR of 13.1% is forecasted from 2022 to 2027 for the animal healthcare market.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.71 EUR | -8.74% | -8.97% | -51.03% |
Apr. 23 | TheraVet SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 13 | TheraVet SA Announces the Launch of BIOCERA-VET Equine | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-51.03% | 2.69M | |
-1.93% | 103B | |
+0.41% | 95.71B | |
+1.69% | 22.02B | |
-17.38% | 20.9B | |
-9.30% | 17.85B | |
-41.01% | 16.21B | |
-14.93% | 15.52B | |
+3.46% | 13.86B | |
+35.19% | 12.04B |
- Stock Market
- Equities
- ALVET Stock
- News TheraVet SA
- TheraVet Signs an International Distribution Agreement for BIOCERA-VET® Covering 24 Countries